Corrigendum to pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study
Name:
Plimack, Powles - Corrigendum.pdf
Size:
315.2Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Plimack, ERPowles, T
Stus, V
Gafanov, R
Nosov, D
Waddell, Tom
Alekseev, B
Poulioti, F
Melichar, B
Soulieres, D
Borchiellini, D
McDermott, RS
Vynnychenko, I
Chang, YH
Tamada, S
Atkins, MB
Li, CX
Perini, R
Molife, LR
Bedke, J
Riniu, BI
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2023
Metadata
Show full item recordCitation
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study ( vol 84 , pg , 449 , 2023). EUROPEAN UROLOGY. 2023 NOV;84(5):E123-E4. PubMed PMID: WOS:001092250500001. English.Journal
European UrologyDOI
10.1016/j.eururo.2023.08.010PubMed ID
37666734Additional Links
https://dx.doi.org/10.1016/j.eururo.2023.08.010Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2023.08.010
Scopus Count
Collections
Related articles
- Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
- Authors: Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, Bedke J, Rini BI
- Issue date: 2024 Feb
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
- Authors: Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI
- Issue date: 2020 Dec
- Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
- Authors: Ding D, Hu H, Shi Y, She L, Yao L, Zhu Y, Zeng S, Shen L, Huang J
- Issue date: 2021 Feb
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
- Authors: Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators
- Issue date: 2019 Mar 21